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a b s t r a c t 
Objectives: To examine whether the case fatality rate (CFR) of COVID-19 decreased over time and whether 
the COVID-19 testing rate is a driving factor for the changes if the CFR decreased. 
Methods: Analyzing COVID-19 cases, deaths and tests in Ontario, Canada, we compared the CFR between 
the first wave and the second wave across 26 public health units in Ontario. We also explored whether a 
high testing rate was associated with a large CFR decrease. 
Results: The first wave CFR ranged from 0.004 to 0.146, whereas the second wave CFR ranged from 
0.003 to 0.034. The pooled RR estimate of second wave COVID-19 case fatality, compared with first wave, 
was 0.24 (95% CI: 0.19-0.32). Additionally, COVID-19 testing percentages were not associated with the 
estimated relative risk ( P = 0.246). 
Conclusions: The COVID-19 CFR decreased significantly in Ontario during the second wave, and COVID-19 
testing was not a driving factor for this decrease. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious 
Diseases. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Introduction 
The COVID-19 pandemic continues to surge globally. Recently, 
many countries experienced a substantial second wave of COVID- 
19 ( James et al., 2021 ). While there were much higher infection 
numbers and in some countries more deaths than those in the 
first wave, a substantial decrease in the case fatality rate (CFR) 
was observed ( https://www.ft.com/content/b3801b63- fbdb- 433b- 
9a46-217405b1109f ). Interestingly, researchers have reported that 
CFR decreased during the first wave indicating that COVID-19 
severity might lessen with time ( Schmidt et al., 2021 ; Anesi et al., 
2021 ). However, prior studies only examined declining CFR in 
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hospitalized patients during the first wave. Because there was 
a higher likelihood of detecting asymptomatic and mildly symp- 
tomatic infections during the second wave, health experts sus- 
pect that increased testing numbers may partially explain the 
decline in CFR ( https://www.ft.com/content/b3801b63-fbdb-433b- 
9a46-217405b1109f ). However, little is known regarding the CFR 
changes between the first and second waves at the population 
level or whether high testing rates were associated with the CFR 
decrease. Determining the magnitude of the CFR decrease and the 
association between COVID-19 testing rates and CFR changes could 
have implications for future public health interventions. 
Methods 
We conducted a cross-sectional study using publicly reported 
COVID-19 cases, deaths, and tests available on the Ontario 
Public Health website as of February 10, 2021 ( https://covid- 
19.ontario.ca/data ). In Ontario, Canada, the peak 7-day moving av- 
https://doi.org/10.1016/j.ijid.2021.06.059 
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND 
license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Figure 1. COVID-19 case fatality in the first versus the second wave in Ontario, Canada 
RR: relative risk 
erage during the first and second waves was 640 in April 2020 
and 4249 in January 2021. As the number of new cases in On- 
tario dropped below 200 per day between late June and early 
September 2020, we used July 31 to separate the first and sec- 
ond waves. We also conducted sensitivity analyses using June 30, 
2020, and August 31, 2020, as the cut-off dates. We determined 
the CFR per public health unit (PHU) for both the first and sec- 
ond waves, defined as the number of deaths divided by the num- 
ber of new cases. PHUs which had no COVID-19 deaths in the 
first or second wave were excluded. We calculated the relative risk 
(RR) of COVID-19 CFR between the 2 waves (the second versus 
the first wave) and the corresponding 95% CI for each PHU. Us- 
ing a random-effects meta-analysis with inverse variance weight- 
ing, we estimated the pooled RR on population-level CFR across 
PHUs. Using meta-regression techniques, we regressed the loga- 
rithm form of effect size by the second wave testing percentage 
(the number of tests divided by the total population). Acknowledg- 
ing that second-wave patients were younger than in the first wave, 
we also analyzed individual-level data. Applying hierarchical gener- 
alized linear models, we estimated the adjusted odds ratio (AOR), 
clustering by PHUs and controlling for patient age, wave, and test- 
ing percentage. 
Results 
Of the 34 PHUs in Ontario, Canada, 26 PHUs had more than 1 
death in the first and second waves and were therefore included 
in the analyses. The first wave CFR ranged from 0.004 to 0.146, 
whereas the second wave CFR ranged from 0.003 to 0.034. There 
Table 1 
Unadjusted and adjusted odds ratio for the analyses using individual-level data 
Individual-level analysis 
Unadjusted Model 1 ∗ Model 2 ∗






Public health unit-level testing 
percentage (continuous variable) 
0.38 
(0.05, 2.81) 
∗ Model 1 adjusted for patient age and wave; model 2 adjusted for age, wave, 
and public health unit-level second-wave testing percentage. 
was substantial variation in the RRs between the 2 waves across 
PHUs ( Figure 1 ). The pooled RR estimate of second wave COVID- 
19 case fatality, compared with first wave, was 0.24 (95% CI: 0.19- 
0.32). Meta-regression models showed that COVID-19 testing per- 
centages were not statistically significantly associated with the es- 
timated RR ( P = 0.246) despite a trend that the higher the percent- 
age of COVID-19 testing, the smaller the effect size, i.e., RR close 
to 1 (Appendix Figure). Individual-level data analyses, adjusting for 
age, revealed that the AOR of the second wave, compared with the 
first wave, was 0.41 (95% CI: 0.38-0.43; Table 1 ). Sensitivity analy- 
ses using 2 different dates to define the second wave reached sim- 
ilar conclusions (data not shown). 
Discussion 
We found that the COVID-19 CFR decreased significantly 
in Ontario during the second wave. Young age contributed 
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to this decrease, but high COVID-19 testing was not a driv- 
ing factor. Potential reasons for the decrease in COVID-19 CFR 
may be attributed to improvement in clinical care: for exam- 
ple, there was increasing evidence to support corticosteroid 
use (Chris Baraniuk, 2021 ), and Canada approved effective 
treatments, such as Remdesivir and Bamlanivimab in July and 
November 2020, respectively ( https://www.canada.ca/en/health- 
canada/services/drugs-health-products/covid19-industry/drugs- 
vaccines-treatments/authorization/list-drugs.html ). Additionally, 
our findings suggest that SARS-CoV-2, despite becoming more 
transmissible, might decline in virulence over time. Indeed, re- 
searchers have demonstrated a dynamic shift in SARS-CoV-2 
variants to those with increased survival ( Esper et al., 2021 ). 
As SARS-CoV-2 genome sequencing in Ontario during the study 
period is lacking, research on the CFR of variants is needed. 
Increased public awareness during the second-wave period, such 
as compliance with wearing masks, could also decrease the viral 
inoculum, leading to milder and asymptomatic infection manifes- 
tations (Gandhi et al., 2020 ). While our random-effects models 
account for PHU-level characteristics, we acknowledge that we are 
unable to control for confounding factors. To evaluate COVID-19 
intervention programs, researchers and policy decision-makers 
should account for the changes in COVID-19 severity. 
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